First of all, if we look at Heath Canada, it is going to make the decision around advocacy and safety. So that's the first hurdle. I think they are in the best position to give you that balance. I think the more specialized the product is, the more safety concerns there are going to be as well. And sometimes it comes down to having the right balance between benefit and safety. It really is the jurisdiction of Health Canada.
All the examples you talked about are exactly the things we are talking about here today. Patients are living in a global world and understand what is available; they are holding on to that last hope about what they have out there. I don't think we provide patients with similar hope or access to what they would have in another province, such as Quebec, or in other countries, such as France, Germany, the U.K., and so on. So, really, I think you hit it on the nail here by saying that we will see more and more patients frustrated that there is something out there that potentially—and potentially is what I'm saying—could help them, but which they cannot get access to. They will ask, where did the system fail me?
I think that's where CDR plays an important role. Because their approach is predominately one of cost containment, they are going to deny many of these products to patients who are really at their end and are looking for hope and options.